JP2024513191A5 - - Google Patents
Info
- Publication number
- JP2024513191A5 JP2024513191A5 JP2023559999A JP2023559999A JP2024513191A5 JP 2024513191 A5 JP2024513191 A5 JP 2024513191A5 JP 2023559999 A JP2023559999 A JP 2023559999A JP 2023559999 A JP2023559999 A JP 2023559999A JP 2024513191 A5 JP2024513191 A5 JP 2024513191A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain
- chain
- pain
- clostridium neurotoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW110111559A TW202237176A (zh) | 2021-03-30 | 2021-03-30 | 疼痛及發炎性失調之治療 |
| TW110111559 | 2021-03-30 | ||
| GBPCT/GB2021/050783 | 2021-03-30 | ||
| PCT/GB2021/050783 WO2022208039A1 (en) | 2021-03-30 | 2021-03-30 | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| PCT/GB2022/050807 WO2022208091A1 (en) | 2021-03-30 | 2022-03-30 | Treatment of pain & inflammatory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513191A JP2024513191A (ja) | 2024-03-22 |
| JP2024513191A5 true JP2024513191A5 (https=) | 2025-04-04 |
Family
ID=83458127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559999A Pending JP2024513191A (ja) | 2021-03-30 | 2022-03-30 | 疼痛及び炎症性障害の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250195626A1 (https=) |
| EP (1) | EP4313120A1 (https=) |
| JP (1) | JP2024513191A (https=) |
| KR (1) | KR20230163470A (https=) |
| AU (1) | AU2022247196A1 (https=) |
| BR (1) | BR112023020057A2 (https=) |
| CA (1) | CA3213914A1 (https=) |
| WO (1) | WO2022208091A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023089343A1 (en) * | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| JP2025534349A (ja) * | 2022-09-30 | 2025-10-15 | イプセン バイオファーム リミテッド | 膀胱痛症候群の治療 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| CN1241945C (zh) | 1998-05-13 | 2006-02-15 | 拜欧特康生化技术开发和咨询有限公司 | 用于抑制肥大细胞脱粒的杂合蛋白质及其用途 |
| DE69910216T2 (de) | 1998-07-22 | 2004-02-19 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| ATE348178T1 (de) | 1999-08-25 | 2007-01-15 | Allergan Inc | Aktivierbare rekombinante neurotoxine |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| AU2005311086B2 (en) | 2004-12-01 | 2012-03-29 | Allergan, Inc. | Fusion proteins |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ATE518882T1 (de) | 2005-09-19 | 2011-08-15 | Allergan Inc | Mit clostridientoxin aktivierbare clostridientoxine |
| WO2008008805A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| UA116985C2 (uk) | 2012-05-30 | 2018-06-11 | Президент Енд Феллоуз Оф Гарвард Колледж | Рекомбінантний ботулінічний нейротоксин |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| WO2016110662A1 (en) | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| PT3274364T (pt) | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3481852B1 (en) | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| TWI822723B (zh) | 2018-01-29 | 2023-11-21 | 英商艾普森生物製藥有限公司 | 非神經元性 SNARE 裂解的肉毒桿菌神經毒素、裂解 hSNAP-23 之活體外方法、及經修飾 BoNT/A L 鏈蛋白酶之用途 |
| WO2019152380A1 (en) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| US20220220466A1 (en) * | 2019-04-17 | 2022-07-14 | Children's Medical Center Corporation | Catalytically inactive botulinum neurotoxin-like toxins and uses thereof |
-
2022
- 2022-03-30 JP JP2023559999A patent/JP2024513191A/ja active Pending
- 2022-03-30 EP EP22716099.1A patent/EP4313120A1/en active Pending
- 2022-03-30 AU AU2022247196A patent/AU2022247196A1/en active Pending
- 2022-03-30 KR KR1020237036646A patent/KR20230163470A/ko active Pending
- 2022-03-30 WO PCT/GB2022/050807 patent/WO2022208091A1/en not_active Ceased
- 2022-03-30 US US18/552,788 patent/US20250195626A1/en active Pending
- 2022-03-30 BR BR112023020057A patent/BR112023020057A2/pt unknown
- 2022-03-30 CA CA3213914A patent/CA3213914A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024513191A5 (https=) | ||
| CN104902915B (zh) | 治疗杜兴氏肌营养不良的卵泡抑素 | |
| US20220153813A1 (en) | Method for promoting wound healing | |
| US10683502B2 (en) | Oligonucleotide decoys for the treatment of pain | |
| JP2025020207A (ja) | 血液脳関門の標的化に有用な組成物および方法 | |
| Sellers et al. | Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration | |
| JP2019533430A5 (https=) | ||
| JP2003532742A (ja) | 神経損傷の修復 | |
| Crisostomo et al. | Nociceptin in rVLM mediates electroacupuncture inhibition of cardiovascular reflex excitatory response in rats | |
| JP2025060836A5 (https=) | ||
| JP2013136586A (ja) | 血液脳関門を通したポリペプチドの非侵襲的な送達およびエンドサイトーシスリガンドの生体内選択 | |
| DE602004001509T2 (de) | Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung | |
| EP2948164B1 (en) | Placenta growth factor in treating duchenne muscular dystrophy | |
| Zhao et al. | The role of neural precursor cells and self assembling peptides in nerve regeneration | |
| Vallejo et al. | Central cardiovascular effects of calcitonin gene-related peptide: interaction with noradrenaline in the nucleus tractus solitarius of rats | |
| US10160791B2 (en) | Protamine in treatment of neuronal injuries | |
| JP2022513626A5 (https=) | ||
| RU2023127652A (ru) | Каталитически неактивные клостридиальные нейротоксины для лечения боли и воспалительных заболеваний | |
| Hayashi et al. | Attenuation of glial scar formation in the injured rat brain by heparin oligosaccharides | |
| US20230070049A1 (en) | Microrna-7 compositions for promoting functional recovery following spinal cord injury and methods of use thereof | |
| CN120818018A (zh) | Fga来源12肽在制备神经损伤修复药物中的用途 | |
| KR20230144870A (ko) | Mincle 억제제를 포함하는 신경병성 통증 치료용 약학 조성물 | |
| Class et al. | Patent application title: PROTAMINE IN TREATMENT OF NEURONAL INJURIES | |
| Aoki et al. | Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy | |
| HK1224554B (en) | Method for promoting wound healing |